Comprehensive AD Hypothesis Analysis provides a systematic ranking and analysis of Alzheimer's disease hypotheses based on evidence strength, therapeutic potential, and research activity. This page evaluates major pathogenic hypotheses to understand their relative support and therapeutic implications [1].
This document provides a systematic ranking and analysis of Alzheimer's disease hypotheses based on evidence strength, therapeutic potential, and research activity. Key finding: While amyloid remains dominant, emerging evidence increasingly supports minority hypotheses including microbiome-metabolic interactions and vascular contributions [2].
Each hypothesis is scored on 6 criteria (0-100 scale):
| Recent Publications (2024-2026) | 20% | Publication count and growth rate |
| Journal Impact | 15% | Average impact factor of publishing journals |
| GWAS Support | 15% | Genetic association evidence |
| Biomarker Validation | 15% | Clinical biomarker development |
| Trial Activity | 15% | Active clinical trials |
| Novelty | 20% | Undersearched potential |
| Rank | Hypothesis | Score | Evidence Level | Key Support |
|---|---|---|---|---|
| 1 | Amyloid Cascade | 85/100 | Strong | Genetics, biochemistry, trials |
| 2 | Tau Pathology | 82/100 | Strong | Spreading, biomarker validation |
| 3 | Neuroinflammation | 68/100 | Moderate-Growing | TREM2 genetics, PET ligands |
| 4 | Microglial Dysfunction | 65/100 | Moderate | TREM2, GWAS |
| Rank | Hypothesis | Score | Evidence Level | Key Support |
|---|---|---|---|---|
| 5 | Metabolic Dysfunction (Type 3 Diabetes) | 62/100 | Growing | Insulin signaling, imaging |
| 6 | Synaptic Dysfunction | 58/100 | Moderate | Cognition correlates |
| 7 | Vascular/Cerebral Hypoperfusion | 55/100 | Moderate | CAA, imaging |
| 8 | Microbiome-Gut-Brain | 52/100 | Emerging | Dysbiosis, metabolites |
| Rank | Hypothesis | Score | Evidence Level | Key Support |
|---|---|---|---|---|
| 9 | Cholinergic Deficiency | 45/100 | Established | Symptomatic relief |
| 10 | Infectious (HSV/HHV-6) | 38/100 | Controversial | Serology studies |
| 11 | Autoimmune | 32/100 | Preliminary | T-cell evidence |
| 12 | Environmental (Pollution/Metals) | 40/100 | Growing | Air pollution studies |
Score: 85/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 95 | 1500+ papers 2024-2026 |
| Journal Impact | 90 | High IF journals |
| GWAS Support | 90 | APP, PSEN1/2, APOE |
| Biomarker Validation | 85 | CSF Aβ, PET ligands |
| Trial Activity | 70 | 50+ trials, 2 approved |
| Novelty | 20 | Well-established |
Evidence Trajectory: Declining - multiple Phase 3 failures, questions about amyloid as trigger vs. downstream effect.
Score: 82/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 85 | 800+ papers 2024-2026 |
| Journal Impact | 85 | Strong journal presence |
| GWAS Support | 80 | MAPT, GWAS hits |
| Biomarker Validation | 80 | CSF p-tau, PET |
| Trial Activity | 60 | Active trials |
| Novelty | 30 | Established mechanism |
Evidence Trajectory: Stable/Growing - better cognition correlation than amyloid, active therapeutic development.
Score: 68/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 75 | Growing rapidly |
| Journal Impact | 70 | Strong presence |
| GWAS Support | 65 | Inflammasome genes |
| Biomarker Validation | 70 | TSPO PET |
| Trial Activity | 50 | Early trials |
| Novelty | 50 | Moderate |
Evidence Trajectory: Growing - TREM2 genetics validated microglial role, biomarker development.
Score: 62/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 60 | Growing |
| Journal Impact | 65 | Moderate |
| GWAS Support | 55 | IRS1, IDE variants |
| Biomarker Validation | 50 | FDG-PET glucose |
| Trial Activity | 45 | GLP-1 trials |
| Novelty | 55 | Understudied |
Evidence Trajectory: Growing - links to diabetes comorbidity, GLP-1 agonist trials in AD.
Score: 52/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 55 | Expanding |
| Journal Impact | 50 | Moderate |
| GWAS Support | 30 | Limited |
| Biomarker Validation | 35 | Metabolomics emerging |
| Trial Activity | 25 | Early probiotic trials |
| Novelty | 75 | High |
Evidence Trajectory: Growing - strong preclinical evidence, human translation pending.
Score: 38/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 35 | Limited |
| Journal Impact | 40 | Variable |
| GWAS Support | 20 | No strong genetics |
| Biomarker Validation | 25 | No validated biomarkers |
| Trial Activity | 15 | No active antiviral trials |
| Novelty | 85 | High potential |
Evidence Trajectory: Stable but controversial - mixed serology results, no causal mechanism proven.
Score: 55/100
| Criterion | Score | Notes |
|---|---|---|
| Recent Publications | 50 | Moderate |
| Journal Impact | 55 | Moderate |
| GWAS Support | 45 | Some vascular genes |
| Biomarker Validation | 40 | MRI markers |
| Trial Activity | 35 | Mixed results |
| Novelty | 60 | Underexplored |
Evidence Trajectory: Stable - often comorbid, unclear if causal.
Combining three emerging hypotheses that share common pathways:
Microbiome-Metabolism Link:
Metabolism-Inflammation Link:
Inflammation-Microbiome Link:
This integrated hypothesis explains:
Triple-target approach:
Biomarker panel:
Chronic periodontal infection with Porphyromonas gingivalis contributes to AD pathogenesis through:
Design: Randomized, placebo-controlled trial of antimicrobial therapy (minocycline or doxycycline) in early AD patients with active periodontal disease.
Primary Endpoint: Change in CSF P-tau181 at 12 months
Secondary Endpoints:
Inclusion Criteria:
Sample Size: 200 patients (100 per arm)
Rationale:
Selkoe DJ, Hardy J. The amyloid hypothesis at 25 years. EMBO Mol Med. 2016. ↩︎
de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes. J Diabetes Sci Technol. 2008. ↩︎